Process analytical technologies in the pharmaceutical industry: the FDA’s PAT initiative

Hinz, Dirk C.
March 2006
Analytical & Bioanalytical Chemistry;Mar2006, Vol. 384 Issue 5, p1036
Academic Journal
Provides information on the process analytical technology (PAT) initiative of the U.S. Food and Drug Administration (FDA) for the pharmaceutical industry. Regulatory and business environment; Development of the PAT initiative; Guidance of the FDA for industry on PAT.


Related Articles

  • Impasse over bill stalls FDA reform.  // H&HN: Hospitals & Health Networks;10/05/97, Vol. 71 Issue 19, p108 

    Reports on the predicament of the bill regarding the restructuring of the regulatory power of the U.S. Food and Drug Administration (FDA). Clinton administration's disagreement on FDA regulatory power; Consumers' opposition on the agency's deregulation measures.

  • New FDA office formed for combination products.  // Ophthalmology Times;2/15/2003, Vol. 28 Issue 4, p6 

    Reports on the formation of the Office of Combination Products within the U.S. Food and Drug Administration to streamline the processing of complex pharmaceutical products.

  • The FDA and regulation of cost-effectiveness claims. Neumann, Peter J.; Zinner, Darren E. // Health Affairs;Fall1996, Vol. 15 Issue 3, p54 

    Examines the relevance and implications of the Food and Drug Administration's (FDA) draft guidelines on market regulation of cost-effective information on pharmaceutical products in the United States. FDA's alleged lack of expertise and historical mandate; Possible impediment of useful...

  • Washington letter.  // DCI;Jun95, Vol. 156 Issue 6, p8 

    Reports on the criticisms against the US Food and Drug Administration's (FDA) policy on prescription and over the counter drugs. FDA's nonprovision of sufficient weight to data and decisions developed by regulatory agencies; Failure to better exploit user fees in the switch process.

  • Regulatory scorecard: What is happening now!  // Pharmacy Today;Feb2012, Vol. 18 Issue 2, p20 

    The article offers updates on regulatories relevant to pharmaceutical industry in the U.S. including the deadline in receiving comments on funding for clinical research, a meeting organized by the Food and Drug Administration (FDA) on naloxone and a guidance document on health benefits.

  • Pattern seen in OPDP warnings. Weinstein, Deborah // Medical Marketing & Media;Dec2013, Vol. 48 Issue 12, p24 

    The article presents the blog Eye on the U.S. Food and Drug Administration (FDA) which examines the trends of Warning Letter from 2004-2012 and discovered that the agency is more probably to hit a drugmaker over materials related to black-box drugs with a Warning Letter.

  • Another look at managed care marketing. Wechsler, Jill // Pharmaceutical Executive;Mar1998, Vol. 18 Issue 3, p20 

    Reports on the US Food and Drug Administration's (FDA) issuance of a guidance that aims to prevent pharmaceutical companies from using pharmacy benefit management firms (PBMs) to avoid obstacles on acceptable marketing activities. Efforts to prevent companies from using PBMs to convey false and...

  • FDA, ICH Face Challenges In Development of GMPs. MIRASOL, FELIZA // Chemical Market Reporter;03/29/99, Vol. 255 Issue 13, p4 

    Focuses on the revised guidance from the United States Food and Drug Administration (FDA) on the production of active pharmaceutical ingredients (API). Challenges faced by FDA; Factors that determine specificity of API; Information on the API.

  • BACPAC Offers Regulatory Relief. Foster, Andrea // Chemical Market Reporter;06/14/99, Vol. 255 Issue 24, Fine & Specialty Chemicals 99 p14 

    Discusses the benefits of the draft guidance called bulk actives post-approval changes (BACPAC) released by the United States Food and Drug Administration for the pharmaceutical industry. Purpose of BACPAC; Remarks from the Pharmaceutical Research and Manufacturers of America regarding the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics